Mirzaei Siroos, Schweighofer-Zwink Gregor, Ofner Heidemarie, Bektic Jasmin, Fajkovic Harun, von Guggenberg Eisabeth, Ponholzer Anton, Kramer Gero, Lusuardi Lukas, Gabriel Michael, Traub-Weidinger Tatjana, Hacker Marcus, Shariat Shahrokh F
Department of Nuclear Medicine with PET Center, Clinic Ottakring, Vienna, Austria.
Department of Nuclear Medicine and Endocrinology, Paracelsus Medical University Salzburg, Salzburg, Austria.
Wien Klin Wochenschr. 2025 Jun;137(Suppl 4):157-166. doi: 10.1007/s00508-025-02544-4. Epub 2025 Jun 4.
Prostate cancer (PCa) remains a leading cause of cancer-related morbidity and mortality in men. Over the past decades, the incidence has risen in all age groups. Prostate-specific membrane antigen (PSMA)-based theranostics, which involve the use of PSMA-targeting radiopharmaceuticals for both diagnostic imaging and therapeutic applications, have become integral in the management of patients with metastatic castration-resistant prostate cancer (mCRPC). The field has witnessed a substantial and continuously expanding body of scientific literature, encompassing case reports, original research, systematic reviews and also clinical guidelines. The objective of this joint statement is to enhance awareness of PSMA theranostics and underscore their critical role in contemporary precision oncology. We aim to provide a comprehensive yet practical perspective on the current landscape of PSMA-based diagnostic and therapeutic modalities, offering a consensus-driven approach to their clinical application.
前列腺癌（PCa）仍然是男性癌症相关发病和死亡的主要原因。在过去几十年中，各年龄组的发病率均有所上升。基于前列腺特异性膜抗原（PSMA）的诊疗方法，即使用靶向PSMA的放射性药物进行诊断成像和治疗应用，已成为转移性去势抵抗性前列腺癌（mCRPC）患者管理中不可或缺的一部分。该领域见证了大量且不断扩展的科学文献，包括病例报告、原创研究、系统评价以及临床指南。本联合声明的目的是提高对PSMA诊疗方法的认识，并强调其在当代精准肿瘤学中的关键作用。我们旨在就基于PSMA的诊断和治疗方式的当前形势提供一个全面而实用的观点，为其临床应用提供一种基于共识的方法。
